- Home
- FNLC vs CRDF Comparison
FNLC vs CRDF Comparison
Compare FNLC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- CRDF
- Stock Information
- Founded
- FNLC 1864
- CRDF 1999
- Country
- FNLC United States
- CRDF United States
- Employees
- FNLC N/A
- CRDF N/A
- Industry
- FNLC Major Banks
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FNLC Finance
- CRDF Health Care
- Exchange
- FNLC Nasdaq
- CRDF Nasdaq
- Market Cap
- FNLC 284.1M
- CRDF 288.7M
- IPO Year
- FNLC 1999
- CRDF N/A
- Fundamental
- Price
- FNLC $25.08
- CRDF $3.84
- Analyst Decision
- FNLC
- CRDF Strong Buy
- Analyst Count
- FNLC 0
- CRDF 4
- Target Price
- FNLC N/A
- CRDF $12.00
- AVG Volume (30 Days)
- FNLC 17.4K
- CRDF 1.1M
- Earning Date
- FNLC 04-16-2025
- CRDF 05-01-2025
- Dividend Yield
- FNLC 5.69%
- CRDF N/A
- EPS Growth
- FNLC N/A
- CRDF N/A
- EPS
- FNLC 2.43
- CRDF N/A
- Revenue
- FNLC $79,740,000.00
- CRDF $683,000.00
- Revenue This Year
- FNLC N/A
- CRDF N/A
- Revenue Next Year
- FNLC N/A
- CRDF N/A
- P/E Ratio
- FNLC $10.20
- CRDF N/A
- Revenue Growth
- FNLC 0.35
- CRDF 39.96
- 52 Week Low
- FNLC $21.77
- CRDF $2.01
- 52 Week High
- FNLC $31.05
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- FNLC 45.89
- CRDF 46.50
- Support Level
- FNLC $24.34
- CRDF $3.52
- Resistance Level
- FNLC $25.02
- CRDF $4.42
- Average True Range (ATR)
- FNLC 0.58
- CRDF 0.34
- MACD
- FNLC -0.02
- CRDF -0.03
- Stochastic Oscillator
- FNLC 36.27
- CRDF 34.41
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").